Urolithiasis pp 139-143 | Cite as

Cystine Stone — Therapy with Alpha-Mercapto-Propionylglycine — Ten Years of Experience with Forty-Two Patients

  • Richard E. Hautmann


The aim of management in cystinuria is simply to keep the urinary cystine concentration less than supersaturation and, thus, to prevent cystine precipitation and subsequent stone formation. This goal may be achieved by reducing the volume of cystine excreted into the urine1–4, increasing the volume of urine in which the cystine is dissolved5,6, or increasing the solubility of cystine in the urine7 (Table 1). However, in clinical experience with cystinuria treatment, results continue to be poor. The most promising form of therapy at present is changing cystine to a chemically more soluble form. Until now, reliance has been placed primarily on D- penicillamine8. However the drug has serious side effects that limit its application. Alpha-mercapto-propionylglycine (MPG) is a newly developed drug, promising higher effectiveness and lack of toxic side effects9.


EPIDERMOLYSIS BULLOSA Urinary Tract Stone Cystine Stone Toxic Side Effects9 Thiol Disulfide Exchange 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C. E. Dent, and B. Senior, Brit. J. Urol. 27:317 (1955).CrossRefPubMedGoogle Scholar
  2. 2.
    D. R. Smith, F. O. Kolb, and H. A. Harper, J. Urol. 81:61 (1959).PubMedGoogle Scholar
  3. 3.
    M. Lötz, J. T. Potts, Jr., J. M. Holland, W. S. Kiser, and F. C. Bartter, J. Urol. 95:257 (1966).PubMedGoogle Scholar
  4. 4.
    F. O. Kolb, J. M. Earli, and H. A. Harper, Metabolism 16:378 (1967).CrossRefPubMedGoogle Scholar
  5. 5.
    S. R. Weinberg, and P. A. Tabenkin, Arch. Intern. Med. 90:850 (1952).CrossRefGoogle Scholar
  6. 6.
    C. E. Dent, M. Friedman, H. Gree, and L. C. A. Watson, Brit. Med. J. 1:403 (1965).CrossRefPubMedGoogle Scholar
  7. 7.
    S. Z. Freed, J. Urol. 113:96 (1975).PubMedGoogle Scholar
  8. 8.
    J. C. Crawhall, E. F. Scowen, and R. W. Watts, Brit. Med. J. 1:588 (1963).CrossRefPubMedGoogle Scholar
  9. 9.
    R. Hautmann, B. Terhorst, H. W. Stuhlsatz, and W. Lutzeyer, J. Urol. 117:628 (1977).PubMedGoogle Scholar
  10. 10.
    G. S. Stokes, J. T. Potts, Jr., M. Lötz, and F. C. Bartter, Clin. Sci. 35:467 (1968).PubMedGoogle Scholar
  11. 11.
    W. P. Mulvaney, T. Quilter, and A. Mortera, J. Urol. 114:107 (1975).PubMedGoogle Scholar
  12. 12.
    A. P. Ryle, and F. Sanger, Biochem. J. 60:535 (1955).PubMedGoogle Scholar
  13. 13.
    A. Phil, L. Eldjarn, and K. F. Nakken, Acta. Chem. Scand. 12:1357 (1958).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1981

Authors and Affiliations

  • Richard E. Hautmann
    • 1
  1. 1.Department of Urology, Faculty of MedicineRheinisch-Westfälische Technische HochschuleAachenWest Germany

Personalised recommendations